Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID‐19 vaccinations, Western Australia, 22 February to 30 June 2021

Within the first 4 months of the Western Australian COVID‐19 immunisation programme, 49 suspected anaphylaxis cases were reported to the vaccine safety surveillance system. Twelve reports met Brighton Collaboration case definition, corresponding to rates of 15.9 and 17.7 per million doses of Vaxzevr...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2023-02, Vol.53 (2), p.275-279
Main Authors: Shivarev, Alexander, Phillips, Anastasia, Brophy‐Williams, Sam, Ford, Tim, Richmond, Peter, Effler, Paul, McLean‐Tooke, Andrew
Format: Article
Language:English
Subjects:
Adverse Drug Reaction Reporting Systems
AEFI
Anaphylaxis
Anaphylaxis - etiology
Australia - epidemiology
BNT162 Vaccine
ChAdOx1 nCoV-19
Comirnaty
COVID-19
COVID-19 - etiology
COVID-19 Vaccines - adverse effects
COVID‐19 vaccines
Humans
Immunization
Vaccination - adverse effects
Vaxzevria
Western Australia
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Within the first 4 months of the Western Australian COVID‐19 immunisation programme, 49 suspected anaphylaxis cases were reported to the vaccine safety surveillance system. Twelve reports met Brighton Collaboration case definition, corresponding to rates of 15.9 and 17.7 per million doses of Vaxzevria and Comirnaty administered respectively.
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.16001